Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: GlobeNewswire
CARMIEL, Israel, July 25, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (“Protalix” or the “Company”) announced today the entry into a definitive exchange agreement relating to an exchange (the “Exchange”) of $9 million aggregate principal amount of the Company’s outstanding 4.50% Senior Convertible Notes due 2018 (the “Existing Notes”) for $8.55 million aggregate principal amount of newly issued 4.50% Senior Convertible Notes due 2022 (the “4.50% Notes”). The Exchange will be made in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”). Concurrently, the Company announced today the entry into a definitive note purchase agreement relating to the purchase by certain institutional purchasers in a private placement (the “Private Placement”) of $10 million aggregate principal amount of the Company’s 7.50% Senior Secured Convertible Notes due 2021 (the “7.50% Notes” and, together with the 4.50% Notes, the “Notes
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix BioTherapeutics, Inc. (NYSE: PLX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business ResultsPR Newswire
- Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 [Yahoo! Finance]Yahoo! Finance
PLX
Earnings
- 11/6/23 - Beat
PLX
Sec Filings
- 4/3/24 - Form 4
- 3/14/24 - Form 10-K
- 3/14/24 - Form 8-K
- PLX's page on the SEC website